Ausgabe 1/2022
Inhalt (15 Artikel)
Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis
Qian Zhang, Wei Wang, Qi Yuan, Li Li, Yu-Chao Wang, Chuan-Zhen Chi, Chun-Hua Xu
Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis
Takanori Mukozu, Hidenari Nagai, Daigo Matsui, Kunihide Mohri, Go Watanabe, Naoyuki Yoshimine, Makoto Amanuma, Kojiro Kobayashi, Yu Ogino, Yasushi Matsukiyo, Teppei Matsui, Yasuko Daido, Noritaka Wakui, Mie Shinohara, Koichi Momiyama, Koji Higai, Yoshinori Igarashi
Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study
Takenori Ichimura, Miwa Hinata, Daisuke Ichikura, Shinya Suzuki
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway
Deli Wang, Haiqin Bao
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury
Sandra Heuschkel, Theresa Kretschmann, Raphael Teipel, Simone von Bonin, Stephan Richter, Susanne Quick, Nael Alakel, Christoph Röllig, Ekaterina Balaian, Frank Kroschinsky, Holger Knoth, Martin Bornhäuser, Malte von Bonin
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies
Antoinette R. Tan, Nancy Chan, Brian F. Kiesel, Mark N. Stein, Rebecca A. Moss, Jyoti Malhotra, Joseph Aisner, Mansi Shah, Murugesan Gounder, Hongxia Lin, Michael P. Kane, Yong Lin, Jiuping Ji, Alice Chen, Jan H. Beumer, Janice M. Mehnert
4-(N)-Docosahexaenoyl 2’, 2’-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent
Stephanie Hufnagel, Haiyue Xu, Michael F. Colemam, Solange A. Valdes, Kristyn A. Liu, Stephen D. Hursting, Zhengrong Cui
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
Jennifer E. Hibma, Melissa O’Gorman, Sunil Nepal, Sylvester Pawlak, Katherine Ginman, Yazdi K. Pithavala
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms
Keishi Yoshida, Atsushi Fujita, Hidehiko Narazaki, Takeshi Asano, Yasuhiko Itoh
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
Amita Patnaik, Glen J. Weiss, Drew W. Rasco, Lisa Blaydorn, Amy Mirabella, Murali Beeram, Wei Guo, Sharon Lu, Hadi Danaee, Kristen McEachern, Ellie Im, Jasgit C. Sachdev
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
Sukhmani K. Padda, Karen L. Reckamp, Marianna Koczywas, Joel W. Neal, Jun Kawashima, Shengchun Kong, Daniel B. Huang, Mark Kowalski, Heather A. Wakelee
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib
E. M. Tosca, N. Terranova, K. Stuyckens, A. G. Dosne, T. Perera, J. Vialard, P. King, T. Verhulst, J. J. Perez-Ruixo, P. Magni, I. Poggesi
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
Takafumi Ide, Mayu Osawa, Kinjal Sanghavi, Heather E. Vezina
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers
Xue Chen, Feng Yang, Jiao Zhao, Qi Tang, Jianfu Heng, Jun Deng, Jin Zhang, Yong Chen, Kunyan Li, Jing Wang
Retraction Note to: Linc‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis
Chenggang Li, Zhiming Zhao, Zhipeng Zhou, Rong Liu